Product Description
Glutamine is the most abundant and versatile amino acid in the body. Glutamine is the most abundant and versatile amino acid in the body, and is of fundamental importance to intermediary metabolism, interorgan nitrogen exchange via ammonia (NH3) transport between tissues, and pH homeostasis. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266414/)
Mechanisms of Action: GLS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: Orphan Drug - *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Czech | Ecuador | Egypt | Estonia | Finland | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Korea | Latvia | Lebanon | Lithuania | Malaysia | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Emmaus Medical
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Adenocarcinoma|Pancreatic Cancer|Pancreatic Ductal Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| GlutaPanc | P1 |
Active, not recruiting |
Pancreatic Ductal Carcinoma|Pancreatic Cancer|Adenocarcinoma |
2023-07-06 |
23% |
2023-07-19 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |